Session (CTI)

Issue Broader value dimensions are increasingly recognized across healthcare systems, yet HTA frameworks continue to focus primarily on clinical outcomes and healthcare costs. At the same time, policymakers face growing challenges related to aging populations, labor shortages, caregiver burden, and long-term system sustainability. While expanded value assessment may improve HTA and decision-making in reflecting the wider consequences of health interventions, important questions remain regarding HTA remit, normative and methodological standards, evidentiary robustness, consistency across disease areas, and the risk of selective application. Additional challenges include fragmented data infrastructures, limited measurement of non-health outcomes, insufficient interoperability, and a lack of consensus on how broader value dimensions should be operationalized within HTA processes. Overview This panel will explore not only whether broader value dimensions should be incorporated into HTA and healthcare decision-making, but also how implementation can be carried out in a transparent, credible, and methodologically rigorous manner. Systematically including broader dimensions of value requires clear guidance on evidence standards, modeling approaches, data infrastructure, governance structures, and cross-sector collaboration. The discussion will also address key tensions associated with expanded value assessment: how to balance broader societal outcomes against traditional health outcomes; avoid double-counting, inconsistent application across technologies or patient groups; manage differences between stakeholders generating evidence and those making funding decisions; and whether current healthcare systems are sufficiently prepared to operationalize broader value frameworks in routine practice. After an introduction (10min), speakers will present their perspectives (30min), followed by a moderated discussion on implementation challenges and future directions for expanded value assessment (10min) and an interactive audience debate (10min). The panel provides insights relevant for researchers, HTA bodies, policymakers, healthcare leaders, and industry stakeholders.